Biotechnology
Gene editing, cancer biotechnology, regenerative medicine, longevity science and the evidence moving from laboratories into clinical care.
-
Scientists Edited Human Embryos. The Safety Warning Is the Real Story.
A new embryo base-editing study pairs a precise DNA result with a warning that should shape the debate about reproductive use.
-
A Daily Eye Drop Could Take the Glare Out of Night Driving
Phase III data suggest that phentolamine eye drops can reduce glare, halos and other dim-light vision problems by gently shrinking the pupil. The treatment remains experimental and is not FDA-approved.
-
A Migraine Pill Is Being Tested for Just Seven Days a Month
A Phase III trial found that taking atogepant around the menstrual period reduced migraine days compared with placebo. The result is promising, but the difference was modest and the short-course regimen is not yet a newly approved use.
-
Eight-Letter DNA: Scientists Expand Nature’s Alphabet
Eight-letter DNA expands biology’s familiar alphabet. Researchers are testing how molecular machinery reads it, with useful possibilities and major limits.
-
Injectable Mini Livers: Could Tiny Grafts Support an Organ?
Injectable mini livers kept transplanted cells alive and producing proteins in mice. Here is how the grafts work—and what the study cannot yet tell us.
-
The Alzheimer’s Trial That Starts Before Memory Loss
A major trial is testing an Alzheimer’s drug in people who have no memory problems. The ambition is prevention; the evidence still has to catch up.
-
The Weight-Loss Drug That Helped Old Mice Live Longer
Semaglutide has already changed weight-loss medicine. A new study in older female mice asks a bigger question: could its benefits reach into the biology of ageing?
-
A 3D-Printed Patch for Your Knee? The First Human Test Has Begun.
Nanochon has announced the first human procedure using its 3D-printed Chondrograft knee implant. The aim is local cartilage repair; durable benefits still need testing.
-
The FDA Just Approved a Drug That Silences a Toxic Brain Protein
Zanvastro is the first FDA-approved treatment for Alexander disease. Here is how the RNA medicine works, what its small trial showed and its risks.
-
Can Grey Hair Turn Dark Again? The Biology Is Stranger Than You Think
Some human hairs have regained pigment, and mouse studies reveal why colour-producing cells can stop working. Here is what that does—and does not—mean for reversing grey hair.
-
Can a Cancer Drug Deliver Itself Straight to a Tumour? GSK Is Betting $110 Million on the Idea
HMPL-A830 links an EGFR-seeking antibody to a KRAS inhibitor. The design could concentrate a targeted drug inside cancer cells—but it has not yet shown safety or benefit in people.
-
Can a Blood Test Tell Whether a Longevity Treatment Works? 51 Studies Put Biological-Age Clocks to the Test
Researchers compared 16 epigenetic clocks across 51 human intervention studies. Some detected consistent change, many interventions produced no clear signal, and a younger score still does not prove a longer life.